Network Meta-analysis of oral Chinese patent medicine in treatment of knee osteoarthritis

• Published in: Zhongguo zhongyao zazhi Vol. 46; no. 4; p. 981
• Main Authors: Zhao, Jin-Long, Liang, Gui-Hong, Pan, Jian-Ke, Huang, He-Tao, Yang, Wei-Yi, Luo, Ming-Hui, Zeng, Ling-Feng, Li, Jia-Hui, Liu, Jun
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2021
• Subjects: Biological Products; China; Drugs, Chinese Herbal; Humans; Network Meta-Analysis; Nonprescription Drugs; Osteoarthritis, Knee - drug therapy; China; Chinese patent medicine; traditional Chinese medicine; knee osteoarthritis; network Meta-analysis; randomized controlled trial
• ISSN: 1001-5302
• DOI: 10.19540/j.cnki.cjcmm.20200721.502

To evaluate the efficacy and safety of Chinese patent medicine in the treatment of knee osteoarthritis(KOA) with network Meta-analysis, and provide evidence-based medicine evidences for clinical practice. PubMed, Cochrane Library, EMbase, CNKI, Wanfang, VIP and CBM were used to search for clinical randomized controlled trials(RCTs) on Chinese patent medicines for treatment of knee osteoarthritis, with a time limit from the establishment of each database to March 2020. The bias risk assessment tool recommended by Cochrane was used to evaluate the quality of the included RCTs. The network Meta-analysis was performed by Stata 14.0 software. A total of 5 788 patients in 58 RCTs were included, involving 9 kinds of Chinese patent medicines. The results of the network Meta-analysis indicated that in terms of total effective rate, the top three optimal medication regimens were Jinwu Gutong Capsules + Amino Acid Glucose(AAG), Xianling Gubao + AAG and Biqi Capsules; the top three interventions to reduce the VAS score were Panlongqi Tablets > Xianling Gubao + AAG > Xianling Gubao + non steroidal anti-inflammatory drugs(NSAIDs); the top three interventions to reduce the total score of WOMAC were Jintiange Capsules+NSAIDs> Jinwu Gutong Capsules + AAG > Biqi Capsules + NSAIDs; the top three medication schemes with better curative effect to reduce Lequesnse index were Xianling Gubao + NSAIDs > Biqi Capsules + NSAIDs > Jintiange Capsules + NSAIDs; the top three interventions to reduce TNF-α level Xianling Gubao + AAG > Jintiange Capsules > Jintiange Capsules + AAG=Jinwu Gutong Capsules + AAG. In terms of safety, the top five interventions with the least adverse reactions were Biqi Capsules > Jinwu Gutong Capsules > Biqi Capsules + NSAIDs > Xianling Gubao + NSAIDs > Jintiange Capsules. The combined application of Chinese patent medicine and NSADIs or AAG can improve the clinical treatment effect and reduce adverse reactions in KOA patients.